EGFR and non-small cell lung carcinoma: In 2016, a retrospective study including 1522 consecutive NSCLC patients reported that patients with EGFR mutations at the time of diagnosis have a nearly twofold higher risk of brain metastases.74 The results above suggest that the EGFR mutation status could have an influence on the CNS progression of NSCLC.